Boehringer Ingelheim Launches Digital Tools to Help Veterinarians Diagnose EPM with Confidence

Updated, centralized resources include online neurological exam, interactive EPM diagnostic tool
Author:
Updated:
Original:
Don't Stall website screen capture BI

The new Dontstall.com website, developed by Boehringer Ingelheim and presented by Marquis® (15% w/w ponazuril) Antiprotozoal Oral Paste, aims to help veterinarians accurately identify EPM by providing updated diagnostic tools consolidated in a centralized location.

Equine protozoal myeloencephalitis (EPM)—a protozoal disease that causes inflammation of the brain and/or spinal cord in horses—can be difficult to diagnose. That’s because many of the signs of EPM can vary and imitate other health issues, making it easy to overlook.

The new Dontstall.com website, developed by Boehringer Ingelheim and presented by Marquis® (15% w/w ponazuril) Antiprotozoal Oral Paste, aims to help veterinarians accurately identify EPM by providing updated diagnostic tools consolidated in a centralized location. The site includes an online neurological exam form that can be downloaded and shared electronically and an interactive EPM diagnostic tool that walks users through a series of questions (signs, diagnostic procedures, test results) to determine the likelihood of EPM.

“As the equine veterinarian must be an expert in so many areas, the Dontstall.com website helps provide the tools needed to provide a thorough, detailed neurological exam that can then assist the veterinarian in evaluating whether EPM is likely and more testing, such as a spinal tap, is needed,” says Sarah Reuss, VMD, DACVIM, Equine Professional Services Veterinarian for Boehringer Ingelheim.

MARQUIS IMPORTANT SAFETY INFORMATION: The safe use of MARQUIS in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated. In animal safety studies, loose feces, sporadic inappetence, lost weight, and moderate edema in the uterine epithelium were observed. For use in animals only. Not for human use. Keep out of reach of children.

The company worked with a team of veterinarians and researchers specializing in neurological diseases to create the site, including: Steve Reed DVM, DACVIM, Rood & Riddle Equine Hospital; Nicola Pusterla, DVM, PhD, DACVIM, UC Davis School of Veterinary Medicine; Amy Johnson, DVM, DACVIM, University of Pennsylvania School of Veterinary Medicine; Rob MacKay, BVSc, PhD, DACVIM, University of Florida College of Veterinary Medicine.

The site also includes patient-facing resources, such as the downloadable STALL Sheet, which can help the veterinarian educate horse owners about the signs of EPM—stumbling, tilted head, asymmetrical muscle loss, lameness or gait abnormality and leaning against walls.

“While performing a consistent neurological exam and EPM diagnosis are key, anything veterinarians can do to help empower horse owners to identify the signs and get the veterinarian involved sooner can ultimately help the horse as well,” Reuss says.

About the Equine Business of Boehringer Ingelheim

As the global leader in equine health, Boehringer Ingelheim’s main goal is to improve equine patients’ health and quality of life. We are dedicated to providing the latest product technology for the treatment and prevention of disease in horses. Learn more about our product portfolio and what we can offer the veterinary community by visiting https://www.bi-vetmedica.com/species/equine.html.

About Boehringer Ingelheim Animal Health USA, Inc.

Boehringer Ingelheim is the second-largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.

Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringeringelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringeringelheim.com or in the company’s annual report at http://annualreport.boehringeringelheim.com.

MARQUIS® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. EQU-1167-MARQ0619

AAEP-MediaPartner_1968x1100
AVMA-PLIT-logo_resized
BEVA-logo_3757x2100
WEVA-Logo-Dark-Background_1789x1000
NZEVA-logo_1100x1968

ISELP-logo_1100x1968

AAEVT-logo_2050x3667